RxDoctor Payments DataLook up a doctor →

Matthew Campbell, MD

Internal Medicine · Houston, TXNPI 1134380652

Payments from drug & device makers

$6,148,479in general payments, 2019–2025

Across 315 payments — averaging $19,519 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.5M
  • AstraZeneca$2M
  • Exelixis Inc.$941K
  • Janssen Research & Development, LLC$399K
  • Seagen Inc.$309K
  • EMD Serono, Inc.$15K
  • plus $9K from 16 others
$2,655in research payments, 2019–2025

Across 8 payments — averaging $331.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Seagen Inc.$1K
  • Pfizer$1K

What the payments were for

  • Consulting fees$65,54546%
  • Speaking & faculty fees$33,19223%
  • Travel & lodging$36,51826%
  • Food & beverage$6,3364%
  • Education$2040%
  • Entertainment$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,148,479 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,081
Medicare patients
186
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate39$999,367
FotivdaTivozanib Hcl16$437,378
WeliregBelzutifan14$412,544
LenvimaLenvatinib Mesylate14$337,953
InlytaAxitinib12$238,364
Pazopanib Hcl12$41,932
Everolimus17$32,386
EliquisApixaban13$7,864
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$828
Nifedipine ErNifedipine32$817
Ondansetron OdtOndansetron15$692
Oxycodone Hcl13$494
Levothyroxine Sodium68$414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$941,418$999,36739 claims
MerckWelireg$2,260$412,54414 claims
Eisai Inc.Lenvima$2,910$337,95314 claims
PfizerInlyta, Eliquis$2,472,145$246,22725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →